Oral oncology最新文献

{"title":"A case of secondary ameloblastic carcinoma of the mandible and a comparative review of primary and secondary subtypes","authors":"Xin Wei ,&nbsp;Jiayu Shen ,&nbsp;Ce Shi ,&nbsp;Shichen Zhang ,&nbsp;Huanyan Dai ,&nbsp;Zhiyan Wu ,&nbsp;Xi Li ,&nbsp;Zhimin Xu ,&nbsp;Bing Han","doi":"10.1016/j.oraloncology.2026.107848","DOIUrl":"10.1016/j.oraloncology.2026.107848","url":null,"abstract":"<div><h3>Background</h3><div>Ameloblastic carcinoma is an extremely rare malignant odontogenic epithelial tumor, which can be categorized into primary ameloblastic carcinoma and secondary ameloblastic carcinoma. The secondary type typically arises from a pre-existing, histologically confirmed benign ameloblastoma. Owing to the scarcity of clinical reports, the epidemiology, treatment, and prognosis of ameloblastic carcinoma remain poorly understood.</div></div><div><h3>Methods</h3><div>We report and analyze a case of a 49-year-old male with secondary ameloblastic carcinoma of the mandible. Based on preoperative pathological examination indicating squamous cell carcinoma, the patient underwent right mandibular resection, cervical lymph node dissection, and anterolateral femoral flap repair. Postoperatively, the diagnosis of secondary ameloblastic carcinoma was confirmed pathologically. No signs of metastasis or recurrence were observed during the 2-year follow-up. Additionally, we systematically reviewed the literature on the clinical details, treatment, and outcomes of ameloblastic carcinoma from 2000 to 2022, including five cases from our hospital.</div></div><div><h3>Results</h3><div>A total of 35 cases of primary ameloblastic carcinoma and 45 cases of secondary ameloblastic carcinoma were identified. Both types predominantly occur in males, primarily in the mandible, and are mainly treated with surgery. However, they present at different ages. The primary type is characterized by a short disease course and a favorable prognosis, whereas the secondary type usually has a history of ameloblastoma and a poor prognosis.</div></div><div><h3>Conclusion</h3><div>Our study is one of the few in the literature to highlight a high incidence of secondary ameloblastic carcinoma, suggesting that clinicians should be vigilant for malignant transformation in benign ameloblastomas. We hope this research provides valuable insights for clinical management and a theoretical basis for future studies on the pathogenesis of ameloblastic carcinoma.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107848"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refinement of N category in version-nine of AJCC/UICC TNM staging system for nasopharyngeal carcinoma based on the international consensus recommendations for diagnosing extranodal extension","authors":"Jing Zhong ,&nbsp;Hongye Chen ,&nbsp;Zhiwei Yan ,&nbsp;Hanchuan Xu ,&nbsp;Peng Shi ,&nbsp;Peide Zhu ,&nbsp;Yahan Zheng ,&nbsp;Youping Xiao ,&nbsp;Dechun Zheng ,&nbsp;Caizhu Pan ,&nbsp;Yunbin Chen ,&nbsp;Shaojun Lin ,&nbsp;Jianji Pan ,&nbsp;Qiaojuan Guo","doi":"10.1016/j.oraloncology.2026.107866","DOIUrl":"10.1016/j.oraloncology.2026.107866","url":null,"abstract":"<div><h3>Objectives</h3><div>To ascertain the prognostic value of grade 2 imaging extranodal extension (G2 iENE), also called matted nodes (MNs), in nasopharyngeal carcinoma (NPC) based on the 9th-version of AJCC/UICC TNM staging system (TNM-9) and the Head and Neck Cancer International Group (HNCIG)’s criteria for diagnosing iENE, and propose future refinement of the TNM-9 N category.</div></div><div><h3>Materials and methods</h3><div>Non-metastatic NPC patients treated between 2017 and 2018 were screened. MRI data were reviewed for re-staging according to the TNM-9 and iENE status per the HNCIG-criteria. Five-year overall survival (OS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS) were analyzed. Recursive partitioning analysis (RPA) based on the ordinal N category of TNM-9 and the G2 iENE status were performed to propose a refined N category.</div></div><div><h3>Results</h3><div>Totally, 1334 patients were included, with 462 (34.6%) patients presenting with G2 iENE at baseline. Besides N Category, G2 iENE also showed independent prognostic value for OS (HR: 1.453, P = 0.042), PFS (HR: 1.293, P = 0.057) and DMFS (HR: 1.363, P = 0.042). The RPA-N category was then derived: RPA-N0 (N0), RPA-N1 (N1 without G2 iENE), RPA-N2 (N1 with G2 iENE and N2) and RPA-N3 (N3). The RPA-N classification had a lower Akaike information criterion (AIC) and higher C-index for all endpoints, and performed better in hazard consistency, hazard discrimination, sample size balance and outcome prediction when compared to TNM-9.</div></div><div><h3>Conclusions</h3><div>G2 iENE, based on the HNCIG-criteria, constitute an independent adverse prognostic factor for NPC based on the TNM-9. The RPA-N category, which integrated N category of TNM-9 and G2 iENE, demonstrated better performance than N category in TNM-9, further validation in multicenter cohorts is warranted.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107866"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146053360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on “A pilot study of a digital workflow for navigated tumor bed marking to reduce clinical target volume during adjuvant radiotherapy for oral squamous cell carcinoma”","authors":"Jenefar Sudarson","doi":"10.1016/j.oraloncology.2026.107884","DOIUrl":"10.1016/j.oraloncology.2026.107884","url":null,"abstract":"<div><div>The accurate identification of the Clinical Target Volume (CTV) remains a challenge in providing postoperative adjuvant radiation therapy for patients with OSCC, due to postoperative changes in anatomy, along with the inability to define the exact location of the CTV during surgery. Holdorf et al. report on a pilot study assessing the utility of a digital navigation intraoperatively to identify and outline the tumor bed to improve planning of postoperative radiation therapy. Using navigated margins traced on imaging postoperatively, the authors demonstrate a reduction in CTV volume compared with traditional planning. They noted a mean reduction in CTV of 25.71%. Most importantly, the navigated method preserved the anatomic integrity of the CTV. This commentary discusses defining the CTV, including reducing the risk of irradiating healthy tissue while maintaining oncologic safety. This study supports integrating surgical navigation into approach for cancer care and provides evidence for further studies evaluating the long-term oncologic and radiation-related side effects. These data mark progress toward providing individualized adjuvant radiation therapy for patients with head and neck cancer.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107884"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carcinoma of the parotid Gland: A Population-Based study of incidence and treatment outcomes in 1018 patients","authors":"K. Sandström ,&nbsp;L. Farnebo ,&nbsp;A. Hafström ,&nbsp;A. Westerborn ,&nbsp;M. Olin ,&nbsp;E. Hammerlid ,&nbsp;L. Hammarstedt-Nordenvall ,&nbsp;M. Gebre-Medhin ,&nbsp;B. Granström ,&nbsp;T. Andersson-Säll ,&nbsp;G. Laurell","doi":"10.1016/j.oraloncology.2026.107863","DOIUrl":"10.1016/j.oraloncology.2026.107863","url":null,"abstract":"<div><h3>Intro</h3><div>Population-based studies predominantly focused on carcinoma of the parotid gland (CPG) are rare. The study aims were to analyze the incidence of CPG and to assess treatment outcomes in relation to histopathology, preoperative diagnosis and adjuvant radiotherapy.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on data from the Swedish Head and Neck Cancer Register (SweHNCR), including 1,018 patients diagnosed with CPG between 2008 and 2019.</div></div><div><h3>Results</h3><div>The age-adjusted incidence remained stable with a mean of 0.9 (range 0.65–1.08) cases per 100,000 person-years (ASR-Europe). Curative treatment was administered to 90 % of the patients, with a recurrence rate of 9 % within 3 years. The highest recurrence rates were observed in patients with salivary duct carcinoma and adenocarcinoma, while patients with acinic cell and mucoepidermoid carcinomas had lower recurrence rates. For stage I–II tumors, the 5-year relative survival was unaffected by whether the malignant diagnosis was known preoperatively. Male sex, increasing age, stage III–IV disease, and a World Health Organization/ Eastern Cooperative Oncology Group (WHO/ECOG) performance status 2–4 was independently associated with increased overall mortality risk, whereas the timing of adjuvant radiotherapy was not.</div></div><div><h3>Conclusion</h3><div>This study contributes to establishing the incidence and treatment outcomes of CPG in Sweden and highlights the diverse histopathological diagnoses of these tumors. Notably, unknown malignancy at the time of surgery did not impact survival in early-stage disease, and the timing of postoperative radiotherapy was not associated with overall survival.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107863"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frozen section analysis in HPV-associated squamous cell carcinoma of unknown primary: Clinical and pathological considerations","authors":"Carlos M. Ardila ,&nbsp;Anny Marcela Vivares-Builes ,&nbsp;Eliana Pineda-Vélez","doi":"10.1016/j.oraloncology.2026.107878","DOIUrl":"10.1016/j.oraloncology.2026.107878","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107878"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of osteotomy distance and other predictors of osseous union following mandibular reconstruction with fibula free flap","authors":"Maged Ali Al-Aroomi ,&nbsp;Yiheng Feng ,&nbsp;Naseem Ali Al-Worafi ,&nbsp;Jie Chen ,&nbsp;Ning Li ,&nbsp;Canhua Jiang ,&nbsp;Ye Liang","doi":"10.1016/j.oraloncology.2026.107883","DOIUrl":"10.1016/j.oraloncology.2026.107883","url":null,"abstract":"<div><h3>Objectives</h3><div>Optimal contouring of fibula free flaps (FFF) for mandibulectomy often requires osteotomies. This study aimed to define criteria for initial gap width by evaluating whether postoperative gap size and other factors influence long-term osseous union on CBCT, and to identify key determinants of bone healing.</div></div><div><h3>Methods</h3><div>This retrospective study included 75 patients who underwent segmental mandibulectomy with FFF reconstruction from 2017 to 2024. Initial osteotomy gaps were measured at four points on postoperative CBCT scans. Osseous union was assessed using a callus scale. Demographic, anatomical, and surgical variables—including 3D-assisted planning, fibula morphology, osteotomy location, systemic comorbidities, and segment number —were analyzed using uni- and multivariate regression models.</div></div><div><h3>Results</h3><div>A total of 202 osteotomy sites were evaluated. The mean initial gap was 1.68 ± 0.97 mm, and gap size did not significantly predict long-term union. Complete union occurred in 50.0% of sites, partial union in 36.6%, and nonunion in 13.4%. Fibula–fibula interfaces showed significantly better healing than fibula–mandible interfaces (p &lt; 0.001). Symphyseal osteotomies demonstrated superior union compared with body and angle regions. Systemic vascular comorbidities were strong negative predictors of union, whereas reconstructions using more than two segments showed improved outcomes (p &lt; 0.001). Alcohol consumption negatively affected both initial gap formation and union.</div></div><div><h3>Conclusions</h3><div>Long-term osseous union after FFF reconstruction is influenced mainly by systemic vascular health, osteotomy location, interface type, and fibula morphology rather than initial gap width.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107883"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating betel nut control into routine health management strategies","authors":"Xinjia Cai ,&nbsp;Saman Warnakulasuriya","doi":"10.1016/j.oraloncology.2026.107875","DOIUrl":"10.1016/j.oraloncology.2026.107875","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107875"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic evaluation of microvascular reconstruction of the jaw: A micro-costing analysis and identification of key cost-drivers","authors":"George A. Petrides ,&nbsp;Masako Dunn ,&nbsp;Ashleigh R. Sharman ,&nbsp;Catriona Froggat ,&nbsp;Timothy G.H. Manzie ,&nbsp;Blaise Agresta ,&nbsp;David Beard ,&nbsp;Hansoo Kim ,&nbsp;Michael Boyer ,&nbsp;Rebecca L. Venchiarutti ,&nbsp;Tsu-Hui (Hubert) Low ,&nbsp;David Leinkram ,&nbsp;Sydney Ch’ng ,&nbsp;James Wykes ,&nbsp;Carsten Palme ,&nbsp;Jonathan R. Clark","doi":"10.1016/j.oraloncology.2026.107885","DOIUrl":"10.1016/j.oraloncology.2026.107885","url":null,"abstract":"<div><h3>Purpose</h3><div>Efficient resource allocation in surgery requires thorough economic evaluation that reflects the true costs of a procedure, with micro-costing being a primary method. Existing economic studies on microvascular jaw reconstruction of the jaw often exclude or estimate key cost-drivers. The aim of this study was to estimate the direct financial costs and cost-drivers associated with surgical reconstruction of the jaw from the perspective of the healthcare provider.</div></div><div><h3>Methods</h3><div>A retrospective micro-costing study from the perspective of the healthcare provider was performed on 100 patients who underwent mandibular or maxillary free flap reconstruction. Direct financial costs of activities (in USD) from admission to discharge were examined, and classified into operative and perioperative admission periods.</div></div><div><h3>Results</h3><div>The mean cost for the entire admission was $36,415.95 ± 14,246.56 comprising 57.7% from the operative period and 42.3% from the perioperative admission period. Ward staffing and consumables (35.7%), prostheses (25.0%), and operating room staffing (21.0%) were the largest cost contributors. In adjusted analyses, higher costs were associated with vasculopathy (+$9142.02, p = 0.044), ASA IV ($19,495.93, p = 0.023), tracheostomy (+$10,445.81, p = 0.012), return to the operating room (+$19,920.22, p = 0.005), and return to the intensive care unit (+$25,316.26, p = 0.014).</div></div><div><h3>Conclusion</h3><div>Jaw reconstruction is associated with considerable direct financial costs to the healthcare provider with complications requiring return to the operating room and/or return to the intensive care unit the critical key cost-drivers. These insights will support future health technology assessments focused on jaw reconstruction to assist decision-makers in implementing or reimbursing these procedures.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107885"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-escalation in high-risk HPV-positive OPC: critical appraisal of methodology and inference","authors":"Shu’ang Shu","doi":"10.1016/j.oraloncology.2026.107880","DOIUrl":"10.1016/j.oraloncology.2026.107880","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107880"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic associations of systemic inflammation response index (SIRI) in patients with head and neck cancer: a systematic review and meta-analysis","authors":"Neil D. Almeida ,&nbsp;Tyler V. Schrand ,&nbsp;Daniel Sullivan ,&nbsp;Han Yu ,&nbsp;Song Yao ,&nbsp;Sung Jun Ma ,&nbsp;Andrew Koempel ,&nbsp;Dukagjin Blakaj ,&nbsp;Elizabeth A. Repasky ,&nbsp;Craig M. Brackett ,&nbsp;David W. Goodrich ,&nbsp;Elizabeth G. Bouchard ,&nbsp;Mukund Seshadri ,&nbsp;Mark K. Farrugia ,&nbsp;Anurag K. Singh","doi":"10.1016/j.oraloncology.2026.107859","DOIUrl":"10.1016/j.oraloncology.2026.107859","url":null,"abstract":"<div><div>Background/Objectives: Inflammation and immune evasion are linked to tumor progression. This cancer-related inflammatory response is reflected by a biomarker named the systemic inflammatory response (SIRI). SIRI is calculated by multiplying the peripheral blood neutrophil and monocyte counts and dividing by the lymphocyte count is a biomarker that has shown prognostic capacity in squamous cell head and neck cancer. We sought to perform a <em>meta</em>-analysis of SIRI data for head and neck cancer. Methods: A <em>meta</em>-analysis using a mixed-effects model was performed to estimate the overall effect size of prognostic capacity. The primary outcomes of interest were overall survival and progression-free survival, with effect sizes measured as log hazard ratios (HR). Results: Ten studies reporting data on overall survival revealed a pooled HR of 2.4 (p &lt; 0.0001). This indicates higher SIRI patients are at greater risk of mortality relative to lower SIRI patients. Additionally, 3 studies reported metrics on progression-free survival, with a pooled HR of 2.32 (1.72, 3.13) (p &lt; 0.0001). Minimal heterogeneity was observed for progression-free survival (I2 = 0%, p&lt; 0.74). Conclusions: High SIRI portends worse overall survival. Since SIRI correlates to immune function and demonstrated minimal heterogeneity, these factors are among those most likely to be impacted by altered SIRI parameters.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107859"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}